Fully Funded Two Year MD (Masters) in Biliary Tract Cancer

Publication date: 10.05.2019


University of Manchester/The Christie NHS Foundation Trust
Wilmslow Road
Manchester M204BX 

Job Title

Fully Funded Two Year MD (Masters) in Biliary Tract Cancer

Job Description

Biliary tract cancers (BTCs) encompass cancers of the extrahepatic/intrahepatic bile ducts, gallbladder and ampullary carcinoma. The only potentially curative option is surgical resection; median overall survival (OS) in the advanced setting: 11.7 months with cisplatin/gemcitabine chemotherapy1. BTC may develop through accumulation of genetic/epigenetic alterations; influenced by host immunity, diet, environmental/microbial exposure2. The human intestinal microbiome comprises ~1014 microorganisms that can influence host metabolism, immune system and cancer; the liver/biliary tract are exposed to gut microbiome via portal vein blood flow3. Diet, lifestyle, pharmacological factors (including antibiotics), and pro-/prebiotics can influence intestinal microbiota composition; microbial community imbalance (microbial dysbiosis) can potentiate hepatic steatosis and inflammation, and may promote liver tumour development. Additionally, the microbiome in bile may influence complications post BTC resection4. Furthermore, disruption of the microbiota impairs tumour response to immunotherapy and platinum chemotherapy in mouse tumours5. A better understanding of the role of microbes on BTC surgical outcomes is required, in addition to exploring their role in the efficacy of chemotherapy/immunotherapy in advanced BTC. This study will interrogate an institutional database including >600 patients with a BTC diagnosis for evidence of antibiotic use within 2 months before, or 1 month after, the first administration of platinum-based chemotherapy, and investigate the effects of their use on progression-free and OS. Cox regression analysis will elucidate any prognostic/predictive impact. Within prospective studies investigating (1) neoadjuvant cisplatin/gemcitabine versus upfront surgery in patients with resectable BTC and (2) the benefit of addition of immunotherapy to standard cisplatin/gemcitabine in advanced BTC, oral and gut microbiome samples will be collected at treatment initiation, with matched tumour biopsies/blood samples, when possible, to assess genomic alterations, as well as the density/phenotype of tumour infiltrating/circulating immune cell subsets. Metagenomic studies will examine the differences in the diversity/composition of the patient gut microbiome; correlated with surgical outcomes and tumour response.

Entry Requirements

This studentship is suitable for applicants with a Medical degree and Membership of The Royal College of Physicians (MRCP) or equivalent, who are pursuing a career in Medical Oncology and have an interest in gaining further experience in the field of biliary tract cancer research and clinical trials.

Candidates should hold full General Medical Council [GMC] registration and International English Language Testing System (IELTS) (if appropriate) proficiency (at the time of commencing position).

How to apply

Contact person: Mairead McNamara
Email:  Mairead.McNamara@christie.nhs.uk
Phone: 01614468106 
Please see link below to apply:

Application deadline

Deadline for application is 30 July 2019

ESMO Disclaimer

It is the Advertisers' responsibility to ensure that any material submitted for inclusion on this section of the ESMO website complies with all relevant laws and regulations (including the Data Protection Act 1998).

Individuals applying for the position above should make direct contact with the institution making the offer and are responsible to verify the validity of the offer. The European Society for Medical Oncology will not accept responsibility for any error, omission or inaccuracy in any job advertising materials on this section of the website.

Submissions from individuals seeking jobs/positions will not be accepted.

Job openings at the European Society for Medical Oncology’s headquarters are available on  ESMO is Hiring page and on  LinkedIn.